These fusions lead to ligand- and co-receptor-independent activation of the RET kinase domain (TKD) [5], triggering downstream RAS/MAPK, PI3K/AKT, and JAK/STAT signaling that drives proliferation and tumor progression [3,5,7,8]. The gene discussed is RET; the disease is neoplasm.